The one-time gene therapy ST-920 is heading toward an FDA filing; PTC picked it up at auction after gene-medicine pioneer Sangamo filed for bankruptcy.
Licensing HM17321 from Korea’s Hanmi, Roche is chasing the next frontier in weight loss: shedding fat while preserving the muscle that today’s GLP-1 drugs also strip away.
A Science study traced nine stages of metastasis and found a quiet, immune-evading cell state that, when disrupted, let the immune system fight the spreading cancer.
A US compounding group is marketing an under-the-tongue, unapproved version of the weight-loss drug to private UK clinics — a practice Novo Nordisk says risks patient safety.
The orexin-boosting pill treats the underlying biology of narcolepsy type 1 — keeping patients awake and curbing cataplexy — and opens a lucrative new drug class.
A large proteomics analysis of a landmark Parkinson’s study is now public, aiming to sort patients into subtypes and speed more targeted, biology-driven therapies.
The partnership will use quantum algorithms to design better photosensitizers — molecules that kill tumor cells when hit with light — a task classical computers struggle with.
By deliberately removing the antibody response that can backfire against dengue, researchers built an experimental Zika vaccine that defended mice using T cells instead.
A Financial Times report of merger talks sent AstraZeneca stock lower as analysts questioned why the fast-growing company would take on such a deal. Neither firm has confirmed.
Hebrew University researchers show that the overactive gene switches driving tumor growth physically strain and snap DNA — a stress point that might be turned against cancer.
The partnership pairs Evotec’s AI-driven discovery platforms with Odyssey’s disease biology to find small-molecule drugs for immune-driven conditions.
Strong specialty-medicine sales lifted GSK's second quarter as the drugmaker doubles down on oncology — and braces for looming HIV patent losses.